Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
5 hedge funds and large institutions have $32K invested in Biostar Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
60% more capital invested
Capital invested by funds: $20K → $32K (+$12K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$17.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.57K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$556 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $16K | +$17.4K | +12,482 | New |
|
|
2
Acadian Asset Management
Boston,
Massachusetts
| $11K | -$3.57K | -2,566 | -22% |
|
|
3
UBS Group
Zurich,
Switzerland
| $5K | +$3.4K | +2,446 | +206% |
|
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$556 | -400 | -100% |
|
BSPM Hedge Fund Activity: Q3 2017 in Review
5 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q3 2017, worth a combined $32K — up 60% from $20K a quarter earlier.
Fund positioning in BSPM was balanced in Q3 2017: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $17.4K. The largest seller was Acadian Asset Management, cutting an estimated $3.57K.
- 5 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $32K of Biostar Pharmaceuticals, Inc. stock for Q3 2017, up 60% quarter-over-quarter.
- 1 fund opened new Biostar Pharmaceuticals, Inc. positions in Q3 2017 and 1 closed out, a net change of 0 holders.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q3 2017 was Citadel Advisors, an estimated $17.4K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q3 2017 was Acadian Asset Management, an estimated $3.57K sold.
Based on aggregated 13F filings for Q3 2017.